- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01826409
Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes
August 28, 2013 updated by: Soo-Wan Chae, Chonbuk National University Hospital
This study was conducted to investigate the effects of daily supplementation of fermented red ginseng (FRG) on glycemic status in subjects with impaired fasting glucose (IFG) or type 2 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study was a 4 weeks, randomized, double-blind, placebo-controlled trial.
Forty-two subjects with IFG or type 2 diabetes were randomly allocated to 2 groups to consume placebo or FRG three times per day for 4 weeks.
Fasting and postprandial glucose profiles during meal tolerance test were assessed before and after the intervention.
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jeollabok-do
-
Jeonju, Jeollabok-do, Korea, Republic of, 560-822
- Clincial Trial Center for Functional Foods
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 20-75 years with fasting glucose 100~140 mg/dL at least two of the following
Exclusion Criteria:
- Lipid metabolic disorder
- Acute or chronic inflammatory disease
- Taking medication of corticosteroid within 4 weeks of the study
- Cardiovascular disease (arrhythmia, heart failure, myocardial infarction or patient with pacemaker)
- Allergic or hypersensitive to any of the ingredients in the test products
- Participation in other clinical trials within 2 months
- Abnormal hepatic liver function or renal disease (acute/chronic renal failure or nephrotic syndrome)
- Taking medication of lipid phosphates within 3 months of the study etc,
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo 2.7g/day for 4 weeks
|
|
Experimental: Fermented red ginseng
|
Fermented red ginseng 2.7g/day for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose profiles during meal tolerance test
Time Frame: 4 weeks
|
Fasting and postprandial glucose profiles during meal tolerance test were assessed before(baseline) and after the intervention
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in lipid profiles
Time Frame: 4 weeks
|
Change in lipid profiles were assessed before(baseline) and after the intervention
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Tae Sun Park, MD., PhD, Chonbuk National University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
April 4, 2013
First Submitted That Met QC Criteria
April 5, 2013
First Posted (Estimate)
April 8, 2013
Study Record Updates
Last Update Posted (Estimate)
August 29, 2013
Last Update Submitted That Met QC Criteria
August 28, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WKP-FG7070-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impaired Glucose or Type 2 Diabetes
-
Komisarenko Institute of Endocrinology and MetobolismCompletedType 2 Diabetes | Impaired Glucose Tolerance | Impaired Fasting GlucoseUkraine
-
US Department of Veterans AffairsUniversity of Maryland; National Institutes of Health (NIH); National Institute...CompletedType 2 Diabetes Mellitus | Impaired Glucose Tolerance (Prediabetes)United States
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A... and other collaboratorsRecruitingDiabetes Mellitus, Type 2 | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)United States
-
Instituto de Ciencia y Tecnología de Alimentos...ICTAN-CSIC - Madrid - SpainRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes Mellitus | Prediabetic State | Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)Spain
-
Claes-Göran ÖstensonAraim Pharmaceuticals, Inc.UnknownImpaired Glucose Tolerance | Impaired Fasting Glucose | Diabetes Type 2Sweden
-
The University of Texas Health Science Center at...University of Texas; Takeda Pharmaceuticals North America, Inc.CompletedType 2 Diabetes | Impaired Glucose ToleranceUnited States
-
Liegang LiuCompletedType 2 Diabetes | Impaired Glucose Regulation
-
Attikon HospitalHellenic National Diabetes CenterCompleted
-
Fengmei LianNot yet recruitingObese Impaired Glucose Tolerance | Newly Diagnosed Obese Type 2 Diabetic Patients
-
Guang'anmen Hospital of China Academy of Chinese...Hubei College of Traditional Chinese MedicineUnknownType 2 Diabetes Mellitus | Impaired Glucose Tolerance
Clinical Trials on Fermented Red Ginseng
-
Unity Health TorontoHeart and Stroke Foundation of CanadaCompletedHypertension | Blood Pressure | Endothelial FunctionCanada
-
EuroPharma, Inc.Scientific Center of Drug and Medical Technologies Expertise of the Ministry... and other collaboratorsSuspended
-
Chuncheon Sacred Heart HospitalCompleted
-
Shanghai Jiao Tong University School of MedicineRenJi Hospital; Beijing Obstetrics and Gynecology Hospital; Foshan Fuxing Changcheng... and other collaboratorsCompletedAntioxidative Stress | Healthy AgeingChina
-
The Korean Society of GinsengCompleted
-
Daegu Catholic University Medical CenterThe Korean Society of GinsengCompletedHypertensionKorea, Republic of
-
The Korean Society of GinsengCompleted
-
Jae Hoon LeeIlwha Co.,Ltd.Unknown
-
EuroPharma, Inc.Completed
-
Chonbuk National University HospitalCompletedFatty Liver, NonalcoholicKorea, Republic of